Relay Therapeutics Profit Margin

The latest profit margin for RLAY is -2763.91% as of June 2026. That compares with -3728.45% in the prior-year period — up 25.9% year over year. That is below the Healthcare sector average of 21.34%. Investors often review this figure alongside Relay Therapeutics's historical trend and sector peers before judging valuation or financial health.

Over the past year, RLAY's profit margin moved from -3728.45% to -2763.91% — a 25.9% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Relay Therapeutics's valuation or profitability profile.

Against Healthcare companies, RLAY currently prints -2763.91% for profit margin, while the sector average sits near 21.34%. That is roughly 13054.7% below the sector mean. Large gaps often invite a closer look at Relay Therapeutics's growth, margins, and balance sheet.

Profit Margin shows how effectively Relay Therapeutics converts resources into returns. At -2763.91%, RLAY may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -3728.45% in the prior-year period — up 25.9% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting RLAY's profit margin (-2763.91%), review year-over-year change from -3728.45%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.